Hormonal
Once-weekly subcutaneous semaglutide at 2.4 mg significantly improves heart failure symptoms, exercise capacity, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, independent of weight loss mechanisms.
For patients with HFpEF and obesity, once-weekly semaglutide (2.4 mg) significantly improves heart failure symptoms, exercise capacity, and quality of life. This treatment addresses a major unmet need in this population, offering benefits beyond weight loss alone. Patients should discuss this option with their healthcare provider, considering the potential for gastrointestinal side effects and the significant clinical improvements observed.
In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo.
Why this rating
Large, randomized, double-blind, placebo-controlled trial (STEP-HFpEF) with 529 participants across 13 countries.
Source
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Mikhail Kosiborod et al. · New England Journal of Medicine · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →